

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED The West Virginia Health Care Cooperative, Inc. 400 Fairview Heights Road Summersville, WV 26651; 100 Hoylman Drive Gassaway, WV 26624 REPORT NUMBER(s) 2022001		2. NRC/REGIONAL OFFICE Region 1 475 Allendale Rd Suite 102 King of Prussia, PA 19406
3. DOCKET NUMBER(S) 030-37131	4. LICENSE NUMBER(S) 47-31126-01	5. DATE(S) OF INSPECTION 04/05/2022

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- ☐ 1. Based on the inspection findings, no violations were identified.
- ☐ 2. Previous violation(s) closed.
- ☒ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

1 Non-cited violation(s) were discussed involving the following requirement(s):

10 CFR 35.63(d) requires, in part, that unless otherwise directed by the authorized user a licensee may not use a dosage if the dosage does not fall within the prescribed dosage range or if the dosage differs from the prescribed dosage by more than 20 percent.


Contrary to the above, without being otherwise directed by the authorized user, the licensee used a dosage that did not fall within the prescribed dosage range or the dosage differed from the prescribed dosage by more than 20 percent. Specifically, on December 15, 2021 the licensee administered a dosage of 0.9 mCi of Tc-99m Sulfur Colloid for a gastric emptying scan outside of the prescribed dosage range of 1 mCi to 3 mCi; similarly on December 30, 2021, the licensee administered a dosage of 25.3 mCi of Tc-99m Sestamibi for a parathyroid scan outside of the dosage range of 20 mCi-25 mCi.

This is a Severity Level IV in accordance with section 6.3 of the NRC Enforcement Policy.

- ☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with the NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11. (Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE	Walter Smith		7-11-22
NRC INSPECTOR	Patrick-John Hann	Patrick-John E. Hann <small>Digitally signed by Patrick-John E. Hann Date: 2022.07.01 09:58:41 -04'00'</small>	
BRANCH CHIEF	Anne DeFrancisco	Anne E. DeFrancisco <small>Digitally signed by Anne E. DeFrancisco Date: 2022.07.08 13:43:38 -04'00'</small>	